CN108888798A - A kind of flexible foldable biomembrane and preparation method thereof - Google Patents
A kind of flexible foldable biomembrane and preparation method thereof Download PDFInfo
- Publication number
- CN108888798A CN108888798A CN201811061465.2A CN201811061465A CN108888798A CN 108888798 A CN108888798 A CN 108888798A CN 201811061465 A CN201811061465 A CN 201811061465A CN 108888798 A CN108888798 A CN 108888798A
- Authority
- CN
- China
- Prior art keywords
- biomembrane
- polyurethane
- flexible foldable
- chitosan
- diaphragm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000004814 polyurethane Substances 0.000 claims abstract description 78
- 229920002635 polyurethane Polymers 0.000 claims abstract description 64
- 229920001661 Chitosan Polymers 0.000 claims abstract description 42
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 37
- 229920000615 alginic acid Polymers 0.000 claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 28
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229940072056 alginate Drugs 0.000 claims abstract description 23
- 238000001179 sorption measurement Methods 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 10
- 239000011248 coating agent Substances 0.000 claims abstract description 9
- 238000000576 coating method Methods 0.000 claims abstract description 9
- 238000013467 fragmentation Methods 0.000 claims abstract description 5
- 238000006062 fragmentation reaction Methods 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 206010052428 Wound Diseases 0.000 claims description 28
- 208000027418 Wounds and injury Diseases 0.000 claims description 28
- 239000000463 material Substances 0.000 claims description 23
- -1 poly- ammonia Ester Chemical class 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 229920006264 polyurethane film Polymers 0.000 claims description 11
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- 239000000835 fiber Substances 0.000 claims description 9
- 239000002131 composite material Substances 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 8
- 229920000570 polyether Polymers 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 7
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 7
- 229910021529 ammonia Inorganic materials 0.000 claims description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 7
- 235000010413 sodium alginate Nutrition 0.000 claims description 7
- 239000000661 sodium alginate Substances 0.000 claims description 7
- 229940005550 sodium alginate Drugs 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 238000010041 electrostatic spinning Methods 0.000 claims description 5
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 5
- 230000029663 wound healing Effects 0.000 claims description 5
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims description 4
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000000017 hydrogel Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 229920001971 elastomer Polymers 0.000 claims description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 3
- 229920005615 natural polymer Polymers 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 239000004433 Thermoplastic polyurethane Substances 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- WNPMPFBJTYCQEL-UHFFFAOYSA-N carbonic acid;ethyl carbamate Chemical compound OC(O)=O.CCOC(N)=O WNPMPFBJTYCQEL-UHFFFAOYSA-N 0.000 claims description 2
- 229940045110 chitosan Drugs 0.000 claims description 2
- 239000000806 elastomer Substances 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 239000010773 plant oil Substances 0.000 claims description 2
- 239000002861 polymer material Substances 0.000 claims description 2
- 229920003226 polyurethane urea Polymers 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229920002803 thermoplastic polyurethane Polymers 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229920000148 Polycarbophil calcium Polymers 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229950005134 polycarbophil Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 8
- 210000004400 mucous membrane Anatomy 0.000 abstract description 6
- 210000001519 tissue Anatomy 0.000 abstract description 6
- 230000037314 wound repair Effects 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 210000001215 vagina Anatomy 0.000 abstract description 3
- 210000004291 uterus Anatomy 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000003628 erosive effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- 210000000130 stem cell Anatomy 0.000 description 14
- 229940079593 drug Drugs 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- AYLRODJJLADBOB-QMMMGPOBSA-N methyl (2s)-2,6-diisocyanatohexanoate Chemical compound COC(=O)[C@@H](N=C=O)CCCCN=C=O AYLRODJJLADBOB-QMMMGPOBSA-N 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108010039918 Polylysine Proteins 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229920000656 polylysine Polymers 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 5
- 150000004985 diamines Chemical class 0.000 description 4
- 150000002009 diols Chemical class 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920000117 poly(dioxanone) Polymers 0.000 description 4
- 229920001610 polycaprolactone Polymers 0.000 description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 description 4
- 229940098465 tincture Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 239000004970 Chain extender Substances 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108010020346 Polyglutamic Acid Proteins 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 239000004632 polycaprolactone Substances 0.000 description 3
- 229920002643 polyglutamic acid Polymers 0.000 description 3
- 229920002379 silicone rubber Polymers 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000001228 trophic effect Effects 0.000 description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 210000001736 capillary Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- VJVOFLWZDWLHNR-MRCUWXFGSA-N icosan-9-yl (z)-docos-13-enoate Chemical compound CCCCCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCCCCC\C=C/CCCCCCCC VJVOFLWZDWLHNR-MRCUWXFGSA-N 0.000 description 2
- 229960002182 imipenem Drugs 0.000 description 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229960001699 ofloxacin Drugs 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 2
- 108010011110 polyarginine Proteins 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
- ALVZNPYWJMLXKV-UHFFFAOYSA-N 1,9-Nonanediol Chemical compound OCCCCCCCCCO ALVZNPYWJMLXKV-UHFFFAOYSA-N 0.000 description 1
- JPSKCQCQZUGWNM-UHFFFAOYSA-N 2,7-Oxepanedione Chemical compound O=C1CCCCC(=O)O1 JPSKCQCQZUGWNM-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- VDHWOHDSOHPGPC-UHFFFAOYSA-N 3,3-dihydroxyoxepan-2-one Chemical compound OC1(O)CCCCOC1=O VDHWOHDSOHPGPC-UHFFFAOYSA-N 0.000 description 1
- ULKFLOVGORAZDI-UHFFFAOYSA-N 3,3-dimethyloxetan-2-one Chemical compound CC1(C)COC1=O ULKFLOVGORAZDI-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- YKVIWISPFDZYOW-UHFFFAOYSA-N 6-Decanolide Chemical compound CCCCC1CCCCC(=O)O1 YKVIWISPFDZYOW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- YWNYZQTZOONLGU-UHFFFAOYSA-N C(CC)Cl.[O] Chemical compound C(CC)Cl.[O] YWNYZQTZOONLGU-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 239000009413 Chuanxinlian Substances 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- DNYGXMICFMACRA-XHEDQWPISA-N Gentamicin C2b Chemical compound O1[C@H](CNC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N DNYGXMICFMACRA-XHEDQWPISA-N 0.000 description 1
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical compound N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
- 239000005058 Isophorone diisocyanate Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 239000010103 Podophyllin Substances 0.000 description 1
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 240000000203 Salix gracilistyla Species 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 101150014221 Son gene Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000396377 Tranes Species 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 241000469816 Varus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- OPXFZJLGAZHBMA-BUOGMGTNSA-N [(z)-[(1e)-1-(carbamothioylhydrazinylidene)-3-(1,3-dioxoisoindol-2-yl)butan-2-ylidene]amino]thiourea Chemical compound C1=CC=C2C(=O)N(C(C)\C(\C=N\NC(N)=S)=N\NC(N)=S)C(=O)C2=C1 OPXFZJLGAZHBMA-BUOGMGTNSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-N anhydrous cyanic acid Natural products OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- QVYARBLCAHCSFJ-UHFFFAOYSA-N butane-1,1-diamine Chemical compound CCCC(N)N QVYARBLCAHCSFJ-UHFFFAOYSA-N 0.000 description 1
- SZORMCBRRGPWKG-UHFFFAOYSA-N butanoic acid;pentanoic acid Chemical compound CCCC(O)=O.CCCCC(O)=O SZORMCBRRGPWKG-UHFFFAOYSA-N 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- QNEFNFIKZWUAEQ-UHFFFAOYSA-N carbonic acid;potassium Chemical compound [K].OC(O)=O QNEFNFIKZWUAEQ-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- 229960003408 cefazolin sodium Drugs 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960000479 ceftriaxone sodium Drugs 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- FOTKYAAJKYLFFN-UHFFFAOYSA-N decane-1,10-diol Chemical compound OCCCCCCCCCCO FOTKYAAJKYLFFN-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- ZSPPVLDEEFYYTQ-UHFFFAOYSA-N dimethyl benzene-1,2-dicarboxylate prop-1-ene Chemical compound C=CC.C(C=1C(C(=O)OC)=CC=CC1)(=O)OC ZSPPVLDEEFYYTQ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 229960005082 etohexadiol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229960004273 floxacillin Drugs 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- JBFHTYHTHYHCDJ-UHFFFAOYSA-N gamma-caprolactone Chemical compound CCC1CCC(=O)O1 JBFHTYHTHYHCDJ-UHFFFAOYSA-N 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- DNYGXMICFMACRA-UHFFFAOYSA-N gentamicin C1A Natural products O1C(CNC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N DNYGXMICFMACRA-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- SXCBDZAEHILGLM-UHFFFAOYSA-N heptane-1,7-diol Chemical compound OCCCCCCCO SXCBDZAEHILGLM-UHFFFAOYSA-N 0.000 description 1
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960003666 liquefied phenol Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical class CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960004744 micronomicin Drugs 0.000 description 1
- 235000016337 monopotassium tartrate Nutrition 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229950011346 panipenem Drugs 0.000 description 1
- 150000002961 penems Chemical class 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- KJOMYNHMBRNCNY-UHFFFAOYSA-N pentane-1,1-diamine Chemical compound CCCCC(N)N KJOMYNHMBRNCNY-UHFFFAOYSA-N 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 229940068582 podophyllin Drugs 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000520 poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000141 poly(maleic anhydride) Polymers 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 108010052780 polyasparagine Proteins 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 108010057904 polyisoleucine Proteins 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 108010050934 polyleucine Proteins 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108010087948 polymethionine Proteins 0.000 description 1
- 108010039177 polyphenylalanine Proteins 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 108010000222 polyserine Proteins 0.000 description 1
- 108010011723 polytryptophan Proteins 0.000 description 1
- 108010033949 polytyrosine Proteins 0.000 description 1
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 1
- 229940086065 potassium hydrogentartrate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- GGHDAUPFEBTORZ-UHFFFAOYSA-N propane-1,1-diamine Chemical compound CCC(N)N GGHDAUPFEBTORZ-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
- 239000009306 yunnan baiyao Substances 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Abstract
The present invention provides a kind of flexible foldable biomembrane and preparation method thereof,The flexible foldable biomembrane is formed by inside and outside two layers,Wherein,Outer layer be absorb liquid after can fragmentation medical polyurethane diaphragm,Internal layer is surface of a wound coating,For example it is made of the mixture dressing of chitosan and its derivative or alginates or both,It can be individually used for wound repair,It can also be carried on medicine adsorption layer using preceding be adsorbed on therapeutic agent,Play the role for the treatment of,Wherein the surface of a wound includes skin,Mucous membrane or in-vivo tissue,It is particularly suitable for uterine neck reparation,Foldable flexible biomembrane is manufactured into mushroom shaped,There is a protrusion in centre,Before use,Therapeutic agent is adsorbed in chitosan and its derivative or alginate dressing,When use,With dedicated vagina folder or dedicated pushing tool,Push is covered on uterine neck discharge surface,Protrusion is fixed in introitus,Continue local administration to realize uterus neck,Increase and treats chronic cervical disease such as cervical erosion,The effect of HPV.
Description
Technical field
The invention belongs to field of medical accessory, and in particular to a kind of flexible foldable biomembrane and preparation method thereof is used for
Skin, the adherency of mucous membrane and organ surface, load medicine and repairing and treating.
Background technique
With the development of material science, the biomaterial that can be used as dressing is increasing.The advantages of biological dressing, is main
Be with human compatibility is good, toxic side effect is small, antigenicity is low, has certain water penetration, can reduce the surface of a wound dressing change frequency, reduce bacterium
It falls density and is conducive to the control surface of a wound and further infects, the physical damnification of new granulation tissue can also be effectively reduced.Not by structure
Together, film-type, foam sponge type, gel-type and compound etc. can be divided into.
Film-type is usually the film material made of a kind of material, with homogeneous structural, mainly as short-term dressing
For II degree of burn and thickness skin donor wound.Experiments have shown that (such as nylon, polypropylene fibre, polyurethane, polyvinyl alcohol, gathers polyvinyl many materials
Acrylonitrile, polycaprolactone, polylactic acid, polyaminoacid, polytetrafluoroethylene (PTFE), silicone elastomer etc.) it can be used as dressing use.It draws
The adhesiveness of the porosity for the polytetrafluoroethylene film stretched about 70%~80%, gas permeability and the surface of a wound is good, but use when intensity and
Performance is still undesirable.To adapt to bonding and fixation with body tissue, the inner surface of general film-type dressing is velvet-like.
Compound dressing is generally obtained by two or more Material claddings, mainly as the substitute of long-term covering skin, is used
In the treatment of deep II degree and III degree burn wound, such as PU foam devises one kind for internal layer and porous PTFE composite membrane, silicon rubber
The double-layer artificial skin that human body is easily accepted by, epidermis are the silicon rubber to shield, and internal layer is porous collagen chondroitin sulfate,
Clinic shows to can be used for burn and dermatoplasty have certain biological function.
Since organization engineering skin usually supplies nutrition without vascular system, the epithelium on surface is easy necrosis and falls off, therefore,
The extracellular three dimensional matrix of material requirements as dermal scaffold is easier to induce the generation of capillary and blood vessel, and blood vessel and
Capillary will not change its shape and size after growing into matrix.Desired skin repair membrane should be with some strength, and
Biocompatibility and the good natural polymer of cellular affinity are preferably capable of the growth factor that release promotes cell development, or
The growth that can inhibit bacterium, after timbering material machine-shaping have porous three-dimensional structure be easy to cell grow into, nutrients
Matter and the exchange of metabolin etc..
In recent years, many natural, synthesis high molecular polymers are attempted applied to field of tissue engineering technology, are organizer
The reconstruction of official provides three-dimensional porous cytoskeleton.Chitosan and its derivative is a kind of Natural polycations biological polyoses, tool
There are special physical chemistry and biological characteristics.
Chitosan and its derivative is a kind of biomaterial that source is very wide, has good biocompatibility, does not exempt from
Epidemic focus also has preferable biocidal property, can act on other electronegative macromolecules, form the branch of very strong mechanical performance
Frame material meets the performance requirement of tissue engineering bracket and dressing for skin.It is separately added into chitosan and its derivative solution
Hyaluronic acid or sodium alginate, it is possible to reduce wound scar, hemostasis and blood coagulation, enhance wound healing the effect of.
Cervical disease mainly has inflammation and HPV viruse infection etc., is common gynecological disease, frequently-occurring disease, can cause uterus, defeated ovum
Pipe and pelvic inflammatory disease, it is refractory more, high recurrence rate, physical isolation combines appropriate drug or therapeutic equipments to be presently the most effective means
One of, wherein comparing typically chitosan and its derivative uterine neck reparation patch, although chitosan and its derivative uterine neck reparation
It is attached to cervicitis affected area (columnar epithelial cell of uterine neck and cervical gland pipe surface), the work of biological barrier is played to wound and mucous membrane
With, but the organized compatibility of chitin (or chitosan and its derivative) class dressing is good, hemostatic function is good, anti-infective energy
Power is strong, but adhesiveness and compliance are all poor, and the drug of appendix is easy to fall off with secretion, is unable to ensure the drug of continued administration
Concentration, therapeutic effect are also restricted because of the property of material itself.Seaweed acids dressing moisture pick-up properties is high, can maintain the surface of a wound
One wet environment, it is at low cost, but easily harden, cause the surface of a wound to damage again.Fibroin albumen class dressing has good cell and group
It is good to knit compatibility, oxygen flow permeability, but its water imbibition, toughness, mechanicalness and anti-microbial property are to be improved.Bacteria cellulose
Class dressing non-immunogenicity, good permeable breathable, with surface of a wound close adhesion, mechanical strength and plasticity are strong, but lack one
A effective fermentation system produces with carrying out large-scale low-cost.There is collagen class dressing good biocompatibility hemostasis to promote solidifying, promotion
Cell division differentiation, but stability is weaker, poor flexibility, matter are crisp, not resistant to water, and derives from animal, and there are the danger of infection
Danger.
For this purpose, we use special technological design, using company exclusively can industrialization degradable medical polyurethane
New material has developed the present invention for the better composite repairing material of wound repair, can apply by testing and studying repeatedly
In the reparation of a variety of surface of a wound, wherein the drug of cervical disease can be treated with appendix, so that drug concentration is reached treatment concentration, show
The clinic expection of better clinical advantage, polyurethane uterine neck flexible foldable biomembrane of the invention is worthy of expecting.
Summary of the invention
Present invention aim to address above-mentioned technical problem, a kind of flexible foldable biomembrane and its preparation side are provided
Method can be applied to the reparation of a variety of surface of a wound, improve wound repair effect.
In order to solve the above technical problems, the embodiment of the present invention provides a kind of flexible foldable biomembrane, by inside and outside two layers
Composition, wherein outer layer be absorb liquid after can fragmentation medical polyurethane diaphragm, internal layer be surface of a wound coating.
The shape of the flexible foldable biomembrane can need to design according to the adherency of implant site, such as:For
The shape of skin surface reparation can be two layers of diaphragm composition;Diaphragm for gastric ulcer can be easy to swallow it is spherical;With
It can be tubulose in cavity disease;It can be mushroom for cervical disease;It is spongy for can be for hemostasis.
Wherein, the surface of a wound coating is to carry medicine adsorption layer.Such as by chitosan and its derivative, alginates or both
Mixture dressing composition, can be individually used for wound repair, therapeutic activity Drug absorbability can also carried medicine absorption using preceding
On layer, wherein the surface of a wound includes skin, mucous membrane or in-vivo tissue.
Further, the load medicine adsorption layer includes alginate dressing layer and chitosan and its derivative dressing layer, the shell
Poly- carbohydrates and their derivative dressing layer is adhered on alginate dressing layer, is contacted with the surface of a wound, and playing wound repairing includes skin, mucous membrane
Or the effect of in-vivo tissue.
Wherein, the weight percent of the alginates coating and chitosan and its derivative dressing layer is:
Alginate dressing layer 50-100%
Chitosan and its derivative dressing layer 1-49%.
Wherein, the material for carrying medicine adsorption layer is selected from hydrophilic polymer material, specifically includes:Carbomer, poly- card wave
Phenanthrene, Sodium Hyaluronate, sodium alginate, chitosan and its derivative, polyaminoacid, polypeptide, povidone, hydroxypropyl cellulose, hydroxyl
Propyl methocel, hydroxyethyl cellulose, sodium carboxymethyl starch, polyvinyl alcohol, xanthan gum, modified alginates and its degradation
At the alginate of aminohexose and N-acetylglucosamine, starch-grafted acrylonitrile, starch-grafted hydrophilic monomer, poly- third
Olefin(e) acid salt, vinyl acetate co-polymer, modified poly ethylene alcohols, modified cellulose (such as cellulose graft acrylonitrile, fiber
Ring after plain grafted propylene hydrochlorate, cellulose xanthogenation grafted propylene hydrochlorate, cellulose graft acrylamide, carboxymethyl cellulose
Oxygen chloropropane intersect crosslinking) one of or multiple combinations.
In the present invention, the chitosan and its derivative is specially:
Chitosan and its derivative mainly include acylation, carboxylated, alkylation, esterification, Schiff 's base formed and be crosslinked with
And pass through diisocyanate (IPDI, BDI, LDI, HDI etc.) and modified obtained chitosan derivatives (the PU- shell of polymer diol
Glycan).For example we are chemically reacted to obtain one end with isocyanic acid using polymer diol and lysine diisocyanate
The intermediate of root, intermediate are grafted with the amino on chitosan again, have obtained having elasticity and toughness good.
Wherein, absorb liquid after can fragmentation the medical polyurethane diaphragm be selected from degradable medical polyurethane, specifically
Including:Polyether-type, polyester-polyether type, natural polymer subtype and the biodegradable PU of plant oil type, aliphatic polyether ammonia
Ester, polyurethane-acrylate hydrogel, fatty poly-ester carbonate urethane, polyurethane-urea elastomers, polyurethane-poly dimethyl silicon
Oxygen alkane block copolymer, one or both of polyether thermoplastic polyurethane.It is preferred that degradable polyurethane, specifically includes to rely
Propylhomoserin diisocyanate does the polyurethane of hard section, and soft segment can be with polyalcohol, polyethylene glycol 200, polyethylene glycol 400, poly- second
One of glycol 600 or it is a variety of be initiator, one of LA, GA, CL, PDO, adipic anhydride or a variety of obtain polymer two
Alcohol, chain extension selecting are chosen in particular from ethylene glycol, diethylene glycol (DEG), tetraethylene glycol, 1,3- from chain extender diol or diamine or class diamine
Propylene glycol, 1,4-butanediol, 1,6- hexylene glycol, 1,7- heptandiol, 1,8- ethohexadiol, 1,9- nonanediol, 1,10- decanediol, second
One or both of diamines, propane diamine, butanediamine, pentanediamine, class diamine.
The more preferable soft segment raw material of medical polyurethane diaphragm is selected from one of polyurethane, polyester, polyethers, polyaminoacid
Or two kinds of combinations, it is chosen in particular from poly- valerolactone, poly- ε-decalactone, polylactide, polyglycolide, polylactide and polyglycolide
Copolymer, polylactide-co-glycolide copolymer, poly- 6-caprolactone, polyhydroxybutyrate, poly butyric ester, poly- hydroxyl penta
Acid esters, poly butyric ester -co- valerate, poly- (- dioxane -2,3- diketone of Isosorbide-5-Nitrae), poly- (1,3- dioxane -2- ketone), poly-
P-dioxanone, polyanhydride, polymaleic anhydride, poly- hydroxyl-metacrylate, fibrin, polybutylcyanoacrylate,
Polycaprolactone propylene dimethyl phthalate, poly- β-maleic acid, polycaprolactone butyl acrylate, by castor oil, the poly- hydroxyl of microbial fermentation
Base butyric acid valerate (PHBV) and chemically synthesized polyvinyl alcohol (PVA), the bio-based polyurethane material of preparation, more block polymerizations
Object is such as:From oligomerization caprolactone diol, oligomerization dioxanone glycol, polyether ester multi-block polymer, poly- pivalolactone,
Polyglycolic acid trimethyl carbonate, polycaprolactone-glycolide, poly- (g- ethyl glutamate), polyglycine, polyalanine, poly- figured silk fabrics ammonia
Sour, poly- leucine, poly- isoleucine, polyphenylalanine and polyproline, poly- tryptophan, polyserine, polytyrosine, poly- half Guang
Propylhomoserin, poly- methionine, poly-asparagine, polyglutamine and poly- threonine, poly-aspartate and polyglutamic acid, polylysine,
Poly arginine and polyhistidyl or be different aminoacids polymer polypeptide, preferably with free amine group by basic amino acid
Such as one or both of poly arginine, polylysine and the polyhistidyl combination being polymerized.
Further, the flexible foldable biomembrane prepare material further include promote wound healing high molecular material,
Small-molecule drug with biological anti-inflammatory activity, wherein the high molecular material be Sodium Hyaluronate, zinc hyaluronate, PVA,
PVP, polylysine, polyglutamic acid, chondroitin sulfate, sodium carboxymethylcellulose, chitosan and its derivative, alginate, change
Property the combination of one or both of alginate and its alginate that is degraded into aminohexose and N-acetylglucosamine;Institute
State one or two kinds of combinations that small-molecule drug is polypeptide, amino acid and various anti-inflammatory drugs.
Wherein, recoverable characteristic after the medical polyurethane diaphragm has certain thickness and folds, the medical poly- ammonia
Ester diaphragm with a thickness of 0.02~1mm, selected from using PCL as the degradable medical polyurethane of soft segment.
The present invention also provides a kind of preparation methods of flexible foldable biomembrane, include the following steps:
(1-1) by polyurethane and promotes the high molecular material of wound healing to be spun into a thickness of 0.02- by electrostatic spinning
The medical polyurethane diaphragm of 1mm;
(1-2) chooses, and there is the high molecular material of strong water sorption, adhesive attraction to be prepared into loose porous dressing;
Loose porous dressing prepared by step (1-2) is added suitable quantity of water to be adhered to the medical poly- of step (1-1) preparation by (1-3)
It on urethane diaphragm, then dries, dry or is lyophilized, that is, form flexible foldable biomembrane.
The present invention also provides the preparation methods of another flexible foldable biomembrane, include the following steps:
(2-1) polyurethane and PVP are dissolved with organic solvent, pour the medical polyurethane film being made with a thickness of 0.02-1mm
Piece;
(2-2) chooses, and there is the high molecular material of strong water sorption, adhesive attraction to be prepared into composite fibre or attractive gel;
Composite fibre prepared by step (2-2) or attractive gel are coated uniformly on the doctor of step (2-1) preparation by (2-3)
It with polyurethane film on piece, then dries, dry or is lyophilized, that is, form the flexible foldable biomembrane of different purposes.
The present invention also provides a kind of preparation methods pasted using flexible foldable biology film preparation uterine neck reparation, for treating
Cervical disease includes the following steps:
(3-1) polyurethane and PVP are dissolved with organic solvent, pour and the mushroom doctor with a thickness of 0.02-0.5mm is made
Use polyurethane diaphragm;
(3-2) chooses alginates or chitosan and its derivative or two kinds of mixture is prepared into composite fibre;
Composite fibre prepared by step (3-2) is adhered to doctor prepared by step (3-1) with a little sodium alginate by (3-3)
It with polyurethane film on piece, then dries, dry or is lyophilized, that is, form the flexible foldable uterine neck reparation patch of different purposes.
Flexible foldable biomembrane of the present invention, wherein the side for pasting the surface of a wound can add tool when in use
Medicative bioactive molecule, the bioactive molecule include:Biology is anti-inflammatory, antibacterial, the small molecule of antiviral activity, promotes wound
Mouthful healing active medicine active constituent, protein, polyaminoacid (such as polylysine, polyglutamic acid etc.), polypeptide, nutrition because
The combination of one or both of son and stem cell.Wherein trophic factors is selected from:Nerve growth factor, brain source nerve growth because
Son, neural mitogen, ciliary neurotrophic factor, interleukin-6, fibroblast growth factor, leucocyte inhibit because
It is son, insulin-like growth factor, insulin starch peptide, epidermal growth factor, glial cell line-derived neurotrophic factor, platelet derived
The combination of one or more of growth factor, transforming growth factor β;It is dry thin that the stem cell can be divided into myeloid-lymphoid stem cell, multipotency
Born of the same parents and specially one of energy stem cell.
Flexible foldable biomembrane of the present invention can be used as uterine neck patch and use, using preceding by the medical polyurethane
Diaphragm is adsorbed on diaphragm adsorption orifice;Medical polyurethane diaphragm is released to docile with dedicated vagina folder or transmitting device when use
The protrusion for being equipped with and being embedded in cervix opening is formed, diaphragm can be fixed on palace since diaphragm is mushroom in uterine neck discharge surface
Neck mouth position.
Flexible foldable biomembrane of the present invention can coat the active constituent for treating various diseases on diaphragm,
Specifically include the anti-inflammatory, antibacterial of biology, the small molecule of antiviral activity, the active medicine for promoting wound healing, protein, polypeptide,
The combination of one or both of trophic factors and stem cell.Wherein, trophic factors is selected from:Nerve growth factor, brain source property mind
Through growth factor, neural mitogen, ciliary neurotrophic factor, interleukin-6, fibroblast growth factor, leucocyte
Inhibiting factor, insulin-like growth factor, insulin starch peptide, epidermal growth factor, glial cell line-derived neurotrophic factor, blood are small
The combination of one or more of plate source property growth factor, transforming growth factor β;The stem cell can be divided into myeloid-lymphoid stem cell, more
Energy stem cell and specially energy stem cell, specifically include:Embryonic stem cell, candidate stem cell, bone marrow interstital stem cell, nerve cord are thin
One or both of born of the same parents, muscle stem cell, Osteogenic Stem, endodermal stem cells, retinal stem cells, pancreatic stem cells with
On;Biological anti-inflammatory drug specifically includes antibacterial-anti-inflammatory drug, clinically used at present mainly to have following a few classes:Antibiotics, sulphur
Amine, metronidazole class, antimycotic, Chinese patent drug class.Such as beta-lactam antibiotic:1, penicillin antibiotics:Such as mould
Plain G, ospen, procaine penicillin, Amoxicillin, An Benzyl penicillin, mezlocillin, carbenicillin, Imipenem
(safe energy), Meropenem, Panipenem;2, cephalosporins:Such as, cefalexin (pioneer 4), Cefazolin sodium are (first
Cutting edge of a knife or a sword 5), Cefradine (pioneer 6), cefadroxil, Ceftriaxone Sodium (ceftriaxone);3, hydrocarbon mould alkenes and penems:Such as
Imipenem;4, monocycle class antibiotic:Such as aztreonam;Fluoroquinolones antibiotic medicine:Such as Ciprofloxacin, Ofloxacin, promise
Flucloxacillin, lavo-ofloxacin hydrochloride, gatifloxacin;5, macrolide antibiotics:As roxithromycin, azithromycin, carat are mould
Element;6, aminoglycoside antibiotics:Gentamicin, Amikacin, micronomicin;7, other antibiotic etc., there are also it is middle at
Medicine class, such as:The common three gold plaques active constituent of Yunnan Baiyao, anti-urinary system infection contamination, the infection of the upper respiratory tract are common double yellow
Connect oral solution and its injection, also connect the clear piece active constituent of Pu Shuan, cow-bezoar antitoxic bolus (piece) active constituent, chuanxinlian tablet activity
Ingredient, Chlorogenic Acid in Ying Huang Capsules active constituent, anti-inflammation capsule active constituent, interferon formulation, miaow quinoline not moral, cidofovir, send Trane,
Oil of zedoary turmeric, borneol, phytic acid ketone, Erhuang dissipate, podophyllin, 5% phthiobuzone creme, 0.25% idoxuridine ointment, 30%~50%
Trichloroacetic acid or saturation dichloroacetic acid, 18% Peracetic acid, 10% bigcatkin willow acid+acetic acid, 40% formaldehyde, 2% liquefied phenol, 75%
Ethyl alcohol, 20% tincture of iodine, bromogeramine etc..
To improve the performances such as the sticking of flexible foldable biomembrane, indwelling, can medicine be carried in preparation and is inhaled during the preparation process
Addition promotes the ingredient of drug absorption, release and disintegration when attached layer.For example addition gas-producing disintegrant, acid source can select lemon
Lemon acid, tartaric acid, fumaric acid, adipic acid, malic acid etc.;Alkali source can select sodium carbonate, sodium bicarbonate, saleratus, carbonic acid
Potassium, calcium carbonate etc.;PH adjusting agent can select lactic acid, citric acid, potassium hydrogen tartrate, benzoic acid, alginic acid, sorbic acid, rich horse
Acid, ascorbic acid, stearic acid, oleic acid, ethylenediamine tetra-acetic acid (EDTA), boric acid, Boratex, triethylamine etc..
Above-mentioned technical proposal of the invention has the beneficial effect that:Flexible foldable biomembrane of the invention can be according to need
Various shape is made, outer layer plays the role of that microorganism is isolated, and internal layer mosanom and chitosan and its derivative are covered in wound
Facial position plays the role of lasting physical isolation and drug release to appendix drug, guarantees that local mucous membrane is administered continuously, enhancing treatment
Effect.
Detailed description of the invention
Fig. 1 is the structural schematic diagram of flexible foldable biomembrane in the present invention;
Fig. 2 is the structural schematic diagram of flexible uterine neck reparation patch in the present invention;
Fig. 3 is the structural schematic diagram in the present invention for the foldable biomembrane of tubular flexible of cavity disease.
Description of symbols:
1, medical polyurethane diaphragm;2, alginate dressing layer;3, chitosan and its derivative dressing layer;4, alginates and shell
Poly- carbohydrates and their derivative mixing dressing layer;5, mushroom protrusion.
Specific embodiment
To keep the technical problem to be solved in the present invention, technical solution and advantage clearer, below in conjunction with attached drawing and tool
Body embodiment is described in detail.As shown in Figure 1, the present invention provides a kind of flexible foldable biomembrane, formed by inside and outside two layers,
Wherein, outer layer be absorb liquid after can fragmentation medical polyurethane diaphragm 1, internal layer be surface of a wound coating.
Surface of a wound coating in the present embodiment is made of alginate dressing layer 2 and chitosan and its derivative dressing layer 3,
Contact the surface of a wound is chitosan and its derivative dressing layer 3, and alginate dressing layer 2 is attached on medical polyurethane diaphragm 1, is used
When chitosan and its derivative dressing layer 3 is covered on the surface of a wound, chitosan and its derivative dressing layer 3 play antibacterial promote wound
The effect that mouth is repaired, alginate dressing layer 2 play the role of absorbing sepage, and the medical polyurethane diaphragm 1 of outside is absorbed in sepage
It can be gone to sticks and staves in the case where saturation, be easily peeled off discharge.As shown in Fig. 2, the present invention provides a kind of flexibilities for cervical disease
Uterine neck reparation patch, outer layer are medical polyurethane diaphragm 1, and internal layer is that alginates and chitosan and its derivative mix dressing layer 4, institute
It states medical polyurethane diaphragm and alginate dressing is equipped with the mushroom protrusion 5 of insertion cervix opening, before use, therapeutic agent is applied
It overlays on alginates and chitosan and its derivative mixing dressing layer 4, reparation patch is clamped with dedicated vagina pusher varus, by mushroom
Mushroom shape protrusion 5 is embedded in cervix opening, and alginates and chitosan and its derivative mixing 4 docile of dressing layer are in uterine neck discharge surface.
The shape of flexible foldable biomembrane of the present invention can need to design according to the adherency of implant site, than
Such as:Shape for skin surface reparation can be two layers of diaphragm composition;Diaphragm for gastric ulcer, which can be, to be easy to swallow
It is spherical;For cavity disease to can be tubulose as shown in Figure 3;For cervical disease to can be mushroom as shown in Figure 2;With
It is spongy in can be for hemostasis.
The preparation of polyurethane uterine neck flexible foldable biomembrane of the invention is described in further detail below with reference to several embodiments
Method.
Embodiment 1
Polyurethane is dissolved in chloroform soln by S1-1, is made into 15% solution, is spun into tool using electrostatic spinning technique
Having aperture is 1-15 μm, with a thickness of the diaphragm of 0.1-0.2mm, as medical polyurethane diaphragm;
Alginate fibre and Chitosan powder are uniformly mixed by S1-2, even to be coated in medical polyurethane film obtained by step S1-1
On piece, dry or dry both flexible foldable biomembrane.
Embodiment 2
Polyurethane is dissolved in chloroform soln by S2-1, is made into 15% solution, and PVP is made into 15% solution with ethyl alcohol,
Using electrostatic spinning technique to spray, it is spun into weight ratio 1:1 aperture that has is 1-15 μm, with a thickness of the medical poly- of 0.05-0.1mm
Urethane diaphragm;
S2-2 uniformly coats alginate dressing on a side surface of medical polyurethane diaphragm prepared by step S2-1, applies
Expect that surface coats a strata lysine PU- chitosan derivatives chloroformic solution, that is, forms the flexible foldable biology of the present embodiment
Film.
Embodiment 3
Polyurethane is dissolved in chloroform soln by S3-1, is made into 15% chloroformic solution, is formed in concave-convex type grinding tool,
It heats solvent flashing and forms medical polyurethane diaphragm;
Sodium alginate and chitosan are matched gelled by S3-2, are coated uniformly on the resulting medical polyurethane film of step S3-1
On piece, dries or dries, that is, forms the polyurethane uterine neck flexible foldable biomembrane of the present embodiment.
Embodiment 4
S4-1 will be using 1,3 propylene glycol as chain extender, and it is soft segment that PEG200, which causes the polymer diol that CL is obtained, and LDI is hard section
Polyurethane (molecular weight 7-8 ten thousand), be made into 15% chloroformic solution, form waterproof breathable membrane on grinding tool, form medical poly- ammonia
Ester diaphragm;
S4-2 adds 25% tincture of iodine in the gel solution of sodium alginate and chitosan, is coated uniformly on step S4-1
It on resulting medical polyurethane diaphragm, dries or dries, that is, form the polyurethane antibiotic flexible foldable biomembrane of the present embodiment.
Embodiment 5
S5-1 will be using 1,4 butanediamine as chain extender, and it is soft segment that PEG600, which causes the polymer diol that PDO is obtained, and LDI is hard section
Polyurethane (molecular weight 5-7 ten thousand), be made into 15% chloroformic solution, PVP is made into 15% ethanol solution, the two ratio 3:1, use is quiet
It is 5-20 μm, with a thickness of the porous medical polyurethane diaphragm of 0.1-0.2mm that Electrospinning, which is spun into aperture,;
Zinc hyaluronate and chitosan are matched gelled by S5-2, are coated uniformly on medical polyurethane film obtained by step S5-1
On piece, dry or dry it is spare, that is, formed the present embodiment treatment HPV infection polyurethane uterine neck flexible foldable biomembrane.
Embodiment 6
PU (is the PU of hard section, (molecular weight 5-7 ten thousand), addition by soft segment, lysine diisocyanate of PCL-GA by S6-1
Weight ratio is 3:1 PVP is made into 15% chloroformic solution, is cast in concave-convex type mold, forms the tool with a thickness of 0.05-0.1mm
There is the medical polyurethane diaphragm of waterproof and breathable structure;
PU- chitosan and alginate dressing are uniformly mixed by S6-2 with suitable quantity of water, are coated uniformly on doctor obtained by step S6-1
It with polyurethane film on piece, dries, be lyophilized or dry, that is, form the polyurethane uterine neck flexible foldable biomembrane of the present embodiment.
Embodiment 7
S7-1 by PU (being the PU of hard section, number-average molecular weight 3-4 ten thousand by soft segment, lysine diisocyanate of PCL-GA),
Be made into 15% chloroformic solution, use electrostatic spinning technique be spun into aperture for 1-15 μm, with a thickness of the medical of 0.05-0.1mm
Polyurethane diaphragm;
Sodium carboxymethylcellulose is coated on alginate dressing by S7-2, is adhered to medical polyurethane film obtained by step S6-1
On piece, dries, is lyophilized or dries, that is, forms the flexible foldable biomembrane of the present embodiment.
Embodiment 8
PU (being the PU of hard section, number-average molecular weight 3-4 ten thousand by soft segment, lysine diisocyanate of PC) is made by S8-1
30% chloroformic solution is coated uniformly on mold, dries the medical polyurethane diaphragm to be formed with a thickness of 0.05-0.1mm;
Poly-D-lysine, chitosan and alginate dressing are made into paste by S8-2, are coated uniformly on obtained by step S8-1
On medical polyurethane diaphragm, dries or dry spare, that is, form the flexible foldable biomembrane of the present embodiment.
Embodiment 9
The polyurethane uterine neck flexible foldable biomembrane of the wound more for sepage, preparation method are:
PU (being the PU of hard section, number-average molecular weight 3-4 ten thousand by soft segment, lysine diisocyanate of PDO) is made by S9-1
25% chloroformic solution, is coated uniformly on that be dried on grinding tool with aperture be 1-15 μm, with a thickness of the medical poly- of 0.05-0.1mm
Urethane diaphragm;
The upper surface of the step S9-1 medical polyurethane diaphragm prepared is coated one layer of poly-D-lysine and alginates by S9-2
Dressing mixture dries or dries the polyurethane uterine neck flexible foldable biomembrane for forming the present embodiment.
Embodiment 10
The polylysine PU that S10-1 will be crosslinked with lysine diisocyanate, is made hydrogel with water for injection, is cast in
Grinding tool freeze it is drying at aperture be 1-30 μm, with a thickness of the porous medical polyurethane diaphragm of 0.01-0.5mm;
S10-2 uniformly coats 1% carbomer gel on medical polyurethane diaphragm prepared by step S10-1, then shell is gathered
Sugared dressing docile is dried or is dried in polyurethane film on piece, that is, forms the polyurethane uterine neck flexible foldable biology of the present embodiment
Film.
Embodiment 11
S11-1 by PU (being the PU of hard section, number-average molecular weight 2-3 ten thousand by soft segment, lysine diisocyanate of PCL-GA),
Be made into 35% chloroformic solution, pour build up with aperture be 1-10 μm, with a thickness of the porous membrane of 0.05-0.1mm;
Polylysine PU and the poloxamer188 (weight ratio 1 that S11-2 will be crosslinked with lysine diisocyanate:1),
Be configured to 1% hydrogel with water for injection, be coated uniformly on diaphragm made from S11-1, in docile alginate dressing dry or
Drying, that is, form the flexible foldable biomembrane of the present embodiment.
12 zoopery of embodiment
Female New Zealand White Rabbit 6 are taken, positive test model is made in inoculation albicans strain, is divided into two groups, often
Group 3, the inflammatory cell of vaginal washing fluid, data are as follows when testing 7 days:
Group | Number of elements | PMN | Macrophage | Lymphocyte |
1 | 3 | 101±10.2 | 9.8±4.2 | 1.8±1.2 |
2 | 3 | 98±11.7 | 10.8±3.8 | 2.2±1.7 |
Wherein give chitosan gel rubber+tincture of iodine for the 1st group, coating is primary daily, and the 2nd group is prepared using the embodiment of the present invention 6
Polyurethane uterine neck flexible foldable biomembrane+tincture of iodine, replacement is primary every three days.Treatment cycle be 15 days, appearance see two groups it is equal
Without apparent inflammatory reaction, the inflammatory cell of vaginal washing fluid is tested, data are as follows:
Group | Number of elements | PMN | Macrophage | Lymphocyte |
1 | 3 | 21±1.9 | 2.1±0.7 | It is not detected |
2 | 3 | 8±1.7 | It is not detected | It is not detected |
Experimental result is shown:Polyurethane uterine neck flexible foldable biomembrane prepared by the present invention has physical isolation well
And drug carrying ability, potential applicability in clinical practice are wide.
The above is a preferred embodiment of the present invention, it is noted that for those skilled in the art
For, without departing from the principles of the present invention, several improvements and modifications can also be made, these improvements and modifications
It should be regarded as protection scope of the present invention.
Claims (10)
1. a kind of flexible foldable biomembrane, which is characterized in that formed by inside and outside two layers, wherein outer layer is can after absorbing liquid
The medical polyurethane diaphragm of fragmentation, internal layer are surface of a wound coating.
2. a kind of flexible foldable biomembrane according to claim 1, which is characterized in that the surface of a wound coating can be
Carry medicine adsorption layer.
3. a kind of flexible foldable biomembrane according to claim 1 or 2 and its application, which is characterized in that the load medicine
Adsorption layer includes alginate dressing layer and chitosan and its derivative dressing layer, the chitosan and its derivative dressing layer adherency
On alginate dressing layer.
4. a kind of flexible foldable biomembrane according to claim 3 and its application, which is characterized in that the alginates apply
Layer and the weight percent of chitosan and its derivative dressing layer are:
Alginate dressing layer 50-100%
Chitosan and its derivative dressing layer 1-49%.
5. a kind of flexible foldable biomembrane according to claim 1 or 3, which is characterized in that the load medicine adsorption layer
Material is selected from hydrophilic polymer material, specifically includes:Carbomer, Polycarbophil, Sodium Hyaluronate, sodium alginate, chitosan
And its derivative, polyaminoacid, polypeptide, povidone, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, carboxylic
Methyl starch sodium, polyvinyl alcohol, xanthan gum, modified alginates and its it is degraded into aminohexose and N- acetylglucosamine
Alginate, starch-grafted acrylonitrile, starch-grafted hydrophilic monomer, polyacrylate, vinyl acetate co-polymer, change
One of property polyvinyl alcohol, modified cellulose or multiple combinations.
6. a kind of flexible foldable biomembrane according to claim 1 and its application, which is characterized in that the medical poly- ammonia
Ester diaphragm is selected from degradable polyurethane, specifically includes:Polyether-type, polyester-polyether type, natural polymer subtype and plant oil type
Biodegradable PU, aliphatic poly ether urethane, polyurethane-acrylate hydrogel, fatty poly-ester carbonate urethane, polyurethane-
Urea elastomers, polyurethane-polydimethylsiloxaneblock block copolymers, one or both of polyether thermoplastic polyurethane.
7. a kind of flexible foldable biomembrane according to claim 1 or 2, which is characterized in that the medical polyurethane film
Piece with a thickness of 0.02 ~ 1mm, the medical polyurethane diaphragm is selected from using PCL as the degradable medical polyurethane of soft segment.
8. the preparation method of flexible foldable biomembrane described in a kind of any one of claim 1 ~ 7, which is characterized in that packet
Include following steps:
(1-1)By electrostatic spinning, by polyurethane and the high molecular material of wound healing is promoted to be spun into a thickness of 0.02-1mm's
Medical polyurethane diaphragm;
(1-2)Choosing, there is the high molecular material of strong water sorption, adhesive attraction to be prepared into loose porous dressing;
(1-3)By step(1-2)The loose porous dressing of preparation adds suitable quantity of water to be adhered to step(1-1)The medical polyurethane of preparation
It on diaphragm, then dries, dry or is lyophilized, that is, form flexible foldable biomembrane.
9. the preparation method of flexible foldable biomembrane described in a kind of any one of claim 1 ~ 7, which is characterized in that including
Following steps:
(2-1)Polyurethane and PVP are dissolved with organic solvent, pour and different shape and the medical poly- ammonia with a thickness of 0.02-1mm is made
Ester diaphragm;
(2-2)Choosing, there is the high molecular material of strong water sorption, adhesive attraction to be prepared into attractive gel;
(2-3)By step(2-2)The attractive gel of preparation is coated uniformly on step(2-1)On the medical polyurethane diaphragm of preparation,
Then it dries, dry or is lyophilized, that is, form flexible foldable biomembrane.
10. the preparation method of flexible foldable biomembrane described in a kind of any one of claim 1 ~ 7, which is characterized in that packet
Include following steps:
(3-1)Polyurethane and PVP are dissolved with organic solvent, pour and the mushroom medical poly- ammonia with a thickness of 0.02-0.5mm is made
Ester diaphragm;
(3-2)It chooses alginates or chitosan and its derivative or two kinds of mixture is prepared into composite fibre;
(3-3)By step(3-2)The composite fibre of preparation is with sodium alginate gel uniform fold in step(3-1)The doctor of preparation
It with polyurethane film on piece, dries, dry or is lyophilized, that is, form flexible foldable biomembrane.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811061465.2A CN108888798A (en) | 2018-09-12 | 2018-09-12 | A kind of flexible foldable biomembrane and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811061465.2A CN108888798A (en) | 2018-09-12 | 2018-09-12 | A kind of flexible foldable biomembrane and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108888798A true CN108888798A (en) | 2018-11-27 |
Family
ID=64359869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811061465.2A Pending CN108888798A (en) | 2018-09-12 | 2018-09-12 | A kind of flexible foldable biomembrane and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108888798A (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111265723A (en) * | 2020-01-21 | 2020-06-12 | 南京师范大学 | 3D printed skin and preparation method thereof |
CN111359007A (en) * | 2020-03-23 | 2020-07-03 | 瑞希(重庆)生物科技有限公司 | Modified bacterial cellulose hydrogel dressing and preparation method thereof |
CN111939307A (en) * | 2020-08-21 | 2020-11-17 | 滨州医学院 | Medical composite nanofiber dressing and preparation method and application thereof |
CN112516378A (en) * | 2020-12-02 | 2021-03-19 | 浙江工业大学 | Preparation method of phytic acid/silk fibroin/calcined dolomite bone adhesive |
CN112663344A (en) * | 2020-12-29 | 2021-04-16 | 泉州市伊呗思谷化妆品科技有限公司 | Waterproof moisture-permeable film and preparation method thereof |
CN114214750A (en) * | 2022-01-13 | 2022-03-22 | 天津工业大学 | Flame-retardant polyacrylonitrile composite fiber and preparation method and application thereof |
CN114450229A (en) * | 2019-07-24 | 2022-05-06 | 科劲创销有限公司 | Food container comprising a breathable barrier |
CN114775164A (en) * | 2022-06-21 | 2022-07-22 | 山东华冠智能卡有限公司 | RFID electronic tag substrate capable of being repeatedly folded and preparation method thereof |
CN115624658A (en) * | 2022-10-20 | 2023-01-20 | 苏州纳晶医药技术有限公司 | Degradable uterine cavity administration device and preparation method thereof |
US11760853B2 (en) | 2020-11-30 | 2023-09-19 | Industrial Technology Research Institute | Anti-curling film |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107638587A (en) * | 2017-09-25 | 2018-01-30 | 凯斯蒂南京医疗器械有限公司 | With tissue inducing function without scar regeneration medical dressing and preparation method thereof |
CN108159025A (en) * | 2018-03-05 | 2018-06-15 | 苏州纳晶医药技术有限公司 | A kind of polyurethane uterine neck repair membrane and preparation method thereof |
CN108392667A (en) * | 2018-02-12 | 2018-08-14 | 苏州纳晶医药技术有限公司 | Desalination scar medical dressing with tissue inducing function and preparation method thereof |
-
2018
- 2018-09-12 CN CN201811061465.2A patent/CN108888798A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107638587A (en) * | 2017-09-25 | 2018-01-30 | 凯斯蒂南京医疗器械有限公司 | With tissue inducing function without scar regeneration medical dressing and preparation method thereof |
CN108392667A (en) * | 2018-02-12 | 2018-08-14 | 苏州纳晶医药技术有限公司 | Desalination scar medical dressing with tissue inducing function and preparation method thereof |
CN108159025A (en) * | 2018-03-05 | 2018-06-15 | 苏州纳晶医药技术有限公司 | A kind of polyurethane uterine neck repair membrane and preparation method thereof |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114450229A (en) * | 2019-07-24 | 2022-05-06 | 科劲创销有限公司 | Food container comprising a breathable barrier |
CN111265723A (en) * | 2020-01-21 | 2020-06-12 | 南京师范大学 | 3D printed skin and preparation method thereof |
CN111359007A (en) * | 2020-03-23 | 2020-07-03 | 瑞希(重庆)生物科技有限公司 | Modified bacterial cellulose hydrogel dressing and preparation method thereof |
CN111359007B (en) * | 2020-03-23 | 2022-01-11 | 瑞希(重庆)生物科技有限公司 | Modified bacterial cellulose hydrogel dressing and preparation method thereof |
CN111939307A (en) * | 2020-08-21 | 2020-11-17 | 滨州医学院 | Medical composite nanofiber dressing and preparation method and application thereof |
US11760853B2 (en) | 2020-11-30 | 2023-09-19 | Industrial Technology Research Institute | Anti-curling film |
CN112516378A (en) * | 2020-12-02 | 2021-03-19 | 浙江工业大学 | Preparation method of phytic acid/silk fibroin/calcined dolomite bone adhesive |
CN112663344A (en) * | 2020-12-29 | 2021-04-16 | 泉州市伊呗思谷化妆品科技有限公司 | Waterproof moisture-permeable film and preparation method thereof |
CN114214750A (en) * | 2022-01-13 | 2022-03-22 | 天津工业大学 | Flame-retardant polyacrylonitrile composite fiber and preparation method and application thereof |
CN114214750B (en) * | 2022-01-13 | 2023-09-15 | 天津工业大学 | Flame-retardant polyacrylonitrile composite fiber and preparation method and application thereof |
CN114775164A (en) * | 2022-06-21 | 2022-07-22 | 山东华冠智能卡有限公司 | RFID electronic tag substrate capable of being repeatedly folded and preparation method thereof |
CN115624658A (en) * | 2022-10-20 | 2023-01-20 | 苏州纳晶医药技术有限公司 | Degradable uterine cavity administration device and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108888798A (en) | A kind of flexible foldable biomembrane and preparation method thereof | |
Biswas et al. | Recent advancement of biopolymers and their potential biomedical applications | |
Sensharma et al. | Biomaterials and cells for neural tissue engineering: Current choices | |
Aramwit | Introduction to biomaterials for wound healing | |
Cao et al. | Double crosslinked HLC-CCS hydrogel tissue engineering scaffold for skin wound healing | |
US8163714B2 (en) | Injectable crosslinked and uncrosslinked alginates and the use thereof in medicine and in cosmetic surgery | |
US11511018B2 (en) | Conductive biomimetic skin scaffold material with self-repairing function and a method of preparing the same | |
EP3490624A1 (en) | Nerve guidance conduits, methods of production and uses thereof | |
CN102580166A (en) | Medical bionic transparent film implanting material, and preparation method and application of material | |
CN108159025A (en) | A kind of polyurethane uterine neck repair membrane and preparation method thereof | |
CN107638587A (en) | With tissue inducing function without scar regeneration medical dressing and preparation method thereof | |
CN108392667A (en) | Desalination scar medical dressing with tissue inducing function and preparation method thereof | |
WO2015074176A1 (en) | Hydrophilic electrospinning biological composite stent material used for tissue regeneration and preparation method and application thereof | |
CN101773689B (en) | Surgical repairing patch | |
CN1913929A (en) | Methods and composition for soft tissue feature reconstruction | |
CN1235646C (en) | Method for preparing multifunctional biological repair material | |
CN112384258A (en) | Nanofiber-hydrogel composites for cell and tissue delivery | |
CN114276567B (en) | Bionic hydrogel scaffold for tissue engineering skin construction and preparation method thereof | |
Farzamfar et al. | Polycaprolactone/gelatin nanofibrous scaffolds for tissue engineering | |
Estrada et al. | Neural ECM mimetics | |
CN210056890U (en) | Flexible and foldable biological membrane | |
JP5374496B2 (en) | Medical composition | |
CN108338844B (en) | Degradable skin expander | |
JP2009513290A (en) | Scleral buckling band and manufacturing method thereof | |
CN104940981B (en) | Biologically active external application dressing and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: Workshop 601-3, 6th Floor, Jinhong Industrial Park (Workshop I), No. 72, Jinhong 4th Road, Tangjiawan Town, High tech Zone, Zhuhai City, Guangdong Province, 519000 Applicant after: Zhuhai Aohua Fuwei Medical Technology Co.,Ltd. Address before: 2/F, Building C, Airport Industrial Park, No. 35 Changjiang South Road, Wuxi City, Jiangsu Province, 214142 Applicant before: YUANRONG BIOLOGICAL PHARMACEUTICAL Co.,Ltd. WUXI |
|
CB02 | Change of applicant information | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181127 |
|
WD01 | Invention patent application deemed withdrawn after publication |